At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
AZD1236 +1 moredrug
Likely dose
AZD1236 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, Placebo-controlled, Parallel Group Multi-centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Bood and Uine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Period.
In Brief
A Phase 2 clinical trial evaluating AZD1236 and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 55 participants across 10 sites in 4 countries.
Detailed Summary
The primary aim of this study is to investigate the effects of AZD1236 compared with placebo ("inactive substance") in COPD patients by analysing biomarkers for inflammation and tissue degradation in blood, urine and sputum.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesDenmark, Finland, Netherlands, Norway
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionMay 2009
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartSep 1, 2008
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.8 years ago
Interventions
AZD1236drug
oral tablet, 75 mg, twice daily during 6 weeks
Placebodrug
Dosing to match AZD1236